Clinical collaboration Position Biomea Fusion as a partner for academia and research centers by highlighting ongoing collaborations with Leicester Diabetes Centre and participation in ADA conferences, which signals openness to joint trials, data sharing, and multi-center studies that can expand patient access and accelerate program timelines.

Strategic indication expansion Target diabetes and obesity markets with icovamenib and BMF-650 as oral small molecules, emphasizing potential to complement existing therapies. Propose co-development or combination therapy discussions with metabolic and endocrinology specialists, payers, andKOLs to broaden indications and treatment paradigms.

Clinical leadership Leverage three icovamenib abstracts at ADA and other public presentations to secure speaking engagements, advisory roles, and sponsor opportunities. Use thought leadership to attract collaborations with larger pharma partners seeking innovative metabolic solutions.

Funding and visibility Capitalize on current funding and revenue trajectory to pitch strategic partnerships, license deals, or co-development agreements with larger biopharma companies looking to bolster their metabolic portfolios and accelerate time-to-market for new diabetes and obesity therapies.

Global market reach Emphasize the global burden of diabetes and obesity and Biomea Fusion’s international trial activity and conference presence to engage multinational companies, CROs, and contract manufacturing organizations for expanded clinical operations, manufacturing capacity planning, and regional commercialization partnerships.